1
|
Vitelli-Storelli F, Rubín-García M, Pelucchi C, Benavente Y, Bonzi R, Rota M, Palli D, Ferraroni M, Lunet N, Morais S, Ye W, Plymoth A, Malekzadeh R, Tsugane S, Hidaka A, Aragonés N, Castaño-Vinyals G, Zaridze DG, Maximovich D, Vioque J, García-de-la-Hera M, Zhang ZF, Shigueaki Hamada G, Pakseresht M, Pourfarzi F, Mu L, Boccia S, Pastorino R, Yu GP, Lagiou A, Lagiou P, Negri E, La Vecchia C, Martín V. Family History and Gastric Cancer Risk: A Pooled Investigation in the Stomach Cancer Pooling (STOP) Project Consortium. Cancers (Basel) 2021; 13:3844. [PMID: 34359744 PMCID: PMC8345354 DOI: 10.3390/cancers13153844] [Citation(s) in RCA: 19] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2021] [Revised: 07/14/2021] [Accepted: 07/15/2021] [Indexed: 12/24/2022] Open
Abstract
Although there is a clear relationship between family history (FH) and the risk of gastric cancer (GC), quantification is still needed in relation to different histological types and anatomical sites, and in strata of covariates. The objective was to analyze the risk of GC according to first-degree FH in a uniquely large epidemiological consortium of GC. This investigation includes 5946 cases and 12,776 controls from 17 studies of the Stomach Cancer Pooling (StoP) Project consortium. Summary odds ratios (OR) and the corresponding 95% confidence intervals (CIs) were calculated by pooling study-specific ORs using fixed-effect model meta-analysis techniques. Stratified analyses were carried out by sex, age, tumor location and histological type, smoking habit, socioeconomic status, alcohol intake and fruit consumption. The pooled OR for GC was 1.84 (95% CI: 1.64-2.04; I2 = 6.1%, P heterogeneity = 0.383) in subjects with vs. those without first-degree relatives with GC. No significant differences were observed among subgroups of sex, age, geographic area or study period. Associations tended to be stronger for non-cardia (OR = 1.82; 95% CI: 1.59-2.05 for subjects with FH) than for cardia GC (OR = 1.38; 95% CI: 0.98-1.77), and for the intestinal (OR = 1.92; 95% CI: 1.62-2.23) than for the diffuse histotype (OR = 1.62; 95% CI: 1.28-1.96). This analysis confirms the effect of FH on the risk of GC, reporting an approximately doubled risk, and provides further quantification of the risk of GC according to the subsite and histotype. Considering these findings, accounting for the presence of FH to carry out correct prevention and diagnosis measures is of the utmost importance.
Collapse
Affiliation(s)
- Facundo Vitelli-Storelli
- Grupo de Investigación en Interacciones Gen-Ambiente y Salud (GIIGAS), Institute of Biomedicine (IBIOMED), University of León, 24071 León, Spain; (F.V.-S.); (M.R.-G.); (V.M.)
| | - María Rubín-García
- Grupo de Investigación en Interacciones Gen-Ambiente y Salud (GIIGAS), Institute of Biomedicine (IBIOMED), University of León, 24071 León, Spain; (F.V.-S.); (M.R.-G.); (V.M.)
| | - Claudio Pelucchi
- Department of Clinical Sciences and Community Health, University of Milan, 20133 Milan, Italy; (C.P.); (R.B.); (M.F.); (E.N.); (C.L.V.)
| | - Yolanda Benavente
- Cancer Epidemiology Research Programme, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, 08908 Barcelona, Spain
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), 28029 Madrid, Spain; (N.A.); (G.C.-V.); (J.V.); (M.G.-d.-l.-H.)
| | - Rossella Bonzi
- Department of Clinical Sciences and Community Health, University of Milan, 20133 Milan, Italy; (C.P.); (R.B.); (M.F.); (E.N.); (C.L.V.)
| | - Matteo Rota
- Department of Molecular and Translational Medicine, University of Brescia, 25121 Brescia, Italy;
| | - Domenico Palli
- Cancer Risk Factors and Life-Style Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network, ISPRO, 08518 Florence, Italy;
| | - Monica Ferraroni
- Department of Clinical Sciences and Community Health, University of Milan, 20133 Milan, Italy; (C.P.); (R.B.); (M.F.); (E.N.); (C.L.V.)
| | - Nuno Lunet
- EPIUnit—Instituto de Saúde Pública da Universidade do Porto, 4050-091 Porto, Portugal; (N.L.); (S.M.)
- Departamento de Ciências da Saúde Pública e Forenses e Educação Médica, Faculdade de Medicina da Universidade do Porto, 4200-319 Porto, Portugal
| | - Samantha Morais
- EPIUnit—Instituto de Saúde Pública da Universidade do Porto, 4050-091 Porto, Portugal; (N.L.); (S.M.)
- Departamento de Ciências da Saúde Pública e Forenses e Educação Médica, Faculdade de Medicina da Universidade do Porto, 4200-319 Porto, Portugal
| | - Weimin Ye
- Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, 17177 Stockholm, Sweden; (W.Y.); (A.P.)
| | - Amelie Plymoth
- Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, 17177 Stockholm, Sweden; (W.Y.); (A.P.)
| | - Reza Malekzadeh
- Digestive Oncology Research Center, Digestive Disease Research Institute, Tehran University of Medical Sciences, Tehran 14117-13135, Iran; (R.M.); (M.P.); (F.P.)
| | - Shoichiro Tsugane
- Epidemiology and Prevention Group, Center for Public Health Sciences, National Cancer Center, Tokyo 104-0045, Japan; (S.T.); (A.H.)
| | - Akihisa Hidaka
- Epidemiology and Prevention Group, Center for Public Health Sciences, National Cancer Center, Tokyo 104-0045, Japan; (S.T.); (A.H.)
| | - Nuria Aragonés
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), 28029 Madrid, Spain; (N.A.); (G.C.-V.); (J.V.); (M.G.-d.-l.-H.)
- Cancer Epidemiology Section, Public Health Division, Department of Health of Madrid, 28035 Madrid, Spain
| | - Gemma Castaño-Vinyals
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), 28029 Madrid, Spain; (N.A.); (G.C.-V.); (J.V.); (M.G.-d.-l.-H.)
- IMIM (Hospital del Mar Medical Research Institute), 08003 Barcelona, Spain
- Department of Public health, Universitat Pompeu Fabra (UPF), 08002 Barcelona, Spain
- Barcelona Institute for Global Health-ISGlobal, 08036 Barcelona, Spain
| | - David Georgievich Zaridze
- Department of Epidemiology and Prevention, Russian N.N. Blokhin Cancer Research Center, 115478 Moscow, Russia; (D.G.Z.); (D.M.)
| | - Dmitry Maximovich
- Department of Epidemiology and Prevention, Russian N.N. Blokhin Cancer Research Center, 115478 Moscow, Russia; (D.G.Z.); (D.M.)
| | - Jesus Vioque
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), 28029 Madrid, Spain; (N.A.); (G.C.-V.); (J.V.); (M.G.-d.-l.-H.)
- Instituto de Investigación Sanitaria y Biomédica de Alicante, ISABIAL-UMH, 46020 Alicante, Spain
| | - Manuela García-de-la-Hera
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), 28029 Madrid, Spain; (N.A.); (G.C.-V.); (J.V.); (M.G.-d.-l.-H.)
- Instituto de Investigación Sanitaria y Biomédica de Alicante, ISABIAL-UMH, 46020 Alicante, Spain
| | - Zuo-Feng Zhang
- Department of Epidemiology, UCLA Fielding School of Public Health and Jonsson Comprehensive Cancer Center, Los Angeles, CA 90095-6900, USA;
| | | | - Mohammadreza Pakseresht
- Digestive Oncology Research Center, Digestive Disease Research Institute, Tehran University of Medical Sciences, Tehran 14117-13135, Iran; (R.M.); (M.P.); (F.P.)
- Department of Agricultural, Food and Nutritional Sciences, University of Alberta, Edmonton, AB T6G 2R3, Canada
- Nutritional Epidemiology Group, Centre for Epidemiology and Biostatistics, University of Leeds, Leeds LS2 9JT, UK
| | - Farhad Pourfarzi
- Digestive Oncology Research Center, Digestive Disease Research Institute, Tehran University of Medical Sciences, Tehran 14117-13135, Iran; (R.M.); (M.P.); (F.P.)
- Digestive Disease Research Center, Ardabil University of Medical Sciences, Ardabil 56189-85991, Iran
| | - Lina Mu
- Department of Epidemiology and Environmental Health, School of Public Health and Health Professions, University at Buffalo, Buffalo, NY 14261, USA;
| | - Stefania Boccia
- Section of Hygiene, University Department of Life Sciences and Public Health, Università Cattolica del Sacro Cuore, 20123 Rome, Italy; (S.B.); (R.P.)
- Department of Woman and Child Health and Public Health—Public Health Area, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Roma, Italy
| | - Roberta Pastorino
- Section of Hygiene, University Department of Life Sciences and Public Health, Università Cattolica del Sacro Cuore, 20123 Rome, Italy; (S.B.); (R.P.)
| | - Guo-Pei Yu
- Medical Informatics Center, Peking University, Beijing 100191, China;
| | - Areti Lagiou
- Department of Public and Community Health, School of Public Health, University of West Attica, 12243 Athens, Greece;
| | - Pagona Lagiou
- Department of Hygiene, Epidemiology and Medical Statistics, School of Medicine, National and Kapodistrian University of Athens, 15784 Athens, Greece;
- Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 01451, USA
| | - Eva Negri
- Department of Clinical Sciences and Community Health, University of Milan, 20133 Milan, Italy; (C.P.); (R.B.); (M.F.); (E.N.); (C.L.V.)
| | - Carlo La Vecchia
- Department of Clinical Sciences and Community Health, University of Milan, 20133 Milan, Italy; (C.P.); (R.B.); (M.F.); (E.N.); (C.L.V.)
| | - Vicente Martín
- Grupo de Investigación en Interacciones Gen-Ambiente y Salud (GIIGAS), Institute of Biomedicine (IBIOMED), University of León, 24071 León, Spain; (F.V.-S.); (M.R.-G.); (V.M.)
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), 28029 Madrid, Spain; (N.A.); (G.C.-V.); (J.V.); (M.G.-d.-l.-H.)
| |
Collapse
|
2
|
Kishikawa H, Kimura K, Takarabe S, Kaida S, Nishida J. Helicobacter pylori Antibody Titer and Gastric Cancer Screening. DISEASE MARKERS 2015; 2015:156719. [PMID: 26494936 PMCID: PMC4606161 DOI: 10.1155/2015/156719] [Citation(s) in RCA: 43] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 06/14/2015] [Accepted: 09/06/2015] [Indexed: 02/07/2023]
Abstract
The "ABC method" is a serum gastric cancer screening method, and the subjects were divided based on H. pylori serology and atrophic gastritis as detected by serum pepsinogen (PG): Group A [H. pylori (-) PG (-)], Group B [H. pylori (+) PG (-)], Group C [H. pylori (+) PG (+)], and Group D [H. pylori (-) PG (+)]. The risk of gastric cancer is highest in Group D, followed by Groups C, B, and A. Groups B, C, and D are advised to undergo endoscopy, and the recommended surveillance is every three years, every two years, and annually, respectively. In this report, the reported results with respect to further risk stratification by anti-H. pylori antibody titer in each subgroup are reviewed: (1) high-negative antibody titer subjects in Group A, representing posteradicated individuals with high risk for intestinal-type cancer; (2) high-positive antibody titer subjects in Group B, representing active inflammation with high risk for diffuse-type cancer; and (3) low-positive antibody titer subjects in Group C, representing advanced atrophy with increased risk for intestinal-type cancer. In these subjects, careful follow-up with intervals of surveillance of every three years in (1), every two years in (2), and annually in (3) should be considered.
Collapse
Affiliation(s)
- Hiroshi Kishikawa
- Department of Gastroenterology, Tokyo Dental College, Ichikawa General Hospital, 5-11-13 Sugano, Ichikawa, Chiba 272-8513, Japan
| | - Kayoko Kimura
- Department of Gastroenterology, Tokyo Dental College, Ichikawa General Hospital, 5-11-13 Sugano, Ichikawa, Chiba 272-8513, Japan
| | - Sakiko Takarabe
- Department of Gastroenterology, Tokyo Dental College, Ichikawa General Hospital, 5-11-13 Sugano, Ichikawa, Chiba 272-8513, Japan
| | - Shogo Kaida
- Department of Gastroenterology, Tokyo Dental College, Ichikawa General Hospital, 5-11-13 Sugano, Ichikawa, Chiba 272-8513, Japan
| | - Jiro Nishida
- Department of Gastroenterology, Tokyo Dental College, Ichikawa General Hospital, 5-11-13 Sugano, Ichikawa, Chiba 272-8513, Japan
| |
Collapse
|
6
|
Mattar R, Marques SB, Monteiro MDS, Dos Santos AF, Iriya K, Carrilho FJ. Helicobacter pylori cag pathogenicity island genes: clinical relevance for peptic ulcer disease development in Brazil. J Med Microbiol 2007; 56:9-14. [PMID: 17172510 DOI: 10.1099/jmm.0.46824-0] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
The purpose of this study was to verify whether the presence of any of the Helicobacter pylori cagPAI genes or segments--cagA, cagA promoter, cagE, cagM, tnpB, tnpA, cagT and the left end of the cag II (LEC) region--would be a useful marker for the risk of peptic ulcer disease development. H. pylori DNA extracted from positive urease tests of 150 peptic ulcer patients and 65 dyspeptic controls was analysed by PCR. Duodenal ulcers were present in 110, gastric ulcers in 23 and both gastric and duodenal ulcers in 17 patients. A significant association (P <0.001) was found between a conserved cagPAI and peptic ulcer disease (34 %). The positivity of the cagA gene varied according to the region of the gene that was amplified. The region near to the promoter was present in almost all of the H. pylori isolates (97.2 %). The segment from nt 1764 to 2083 and the extreme right end were frequently deleted in the isolates from the controls (P <0.01). The positivity of the promoter region of cagA and cagT, cagE, cagM and LEC showed a significant difference between the isolates from peptic ulcer patients and from the controls (P <0.01). Patients usually had moderate gastritis; however, the intensity of the active inflammation was higher in the peptic ulcer group (P <0.001). cagT, cagM, LEC and the right end terminus of the cagA-positive H. pylori isolates were associated with a 27-fold, 8-fold, 4-fold and 4-fold risk of peptic ulcer disease, respectively, and may be useful markers to identify individuals at higher risk of peptic ulcer disease development in Brazil.
Collapse
Affiliation(s)
- Rejane Mattar
- Department of Gastroenterology, University of São Paulo School of Medicine, São Paulo, SP, Brazil
| | - Sergio Barbosa Marques
- Department of Gastroenterology, University of São Paulo School of Medicine, São Paulo, SP, Brazil
| | | | | | - Kiyoshi Iriya
- Department of Gastroenterology, University of São Paulo School of Medicine, São Paulo, SP, Brazil
| | - Flair José Carrilho
- Department of Gastroenterology, University of São Paulo School of Medicine, São Paulo, SP, Brazil
| |
Collapse
|